Q2057 Afamitresgene autoleucel
Q-Codes
Also known as: Imlygic, afamitresgene autoleucel, TCR therapy
Afamitresgene autoleucel autologous T-cell immunotherapy targeting PRAME for melanoma and other PRAME-expressing malignancies.
Clinical Context
Autologous T-cell therapy targeting PRAME (Preferentially Expressed Antigen in Melanoma). Used for melanoma and other PRAME+ cancers.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.